LifeTech’s LAmbre™ Plus Device Gains US Insurance Coverage for Clinical Trial

LifeTech Scientific Corporation ( (HK:1302) ) has provided an announcement.

LifeTech Scientific Corporation announced that its LAmbre™ Plus Left Atrial Appendage Closure System has obtained medical insurance coverage for a pre-market clinical trial in the US. This trial, which aims to demonstrate the device’s safety and efficacy, marks a significant step in the company’s international expansion efforts. The device, already used in nearly 40,000 cases worldwide, is expected to gain FDA approval following the trial, enhancing LifeTech’s market positioning and offering potential growth opportunities.

More about LifeTech Scientific Corporation

LifeTech Scientific Corporation is a company incorporated in the Cayman Islands, operating in the medical technology industry. The company specializes in developing advanced medical devices, with a focus on products like the LAmbre™ Left Atrial Appendage Closure System, which is used to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation.

YTD Price Performance: 21.58%

Average Trading Volume: 22,269,050

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$7B

See more data about 1302 stock on TipRanks’ Stock Analysis page.